The “Pharmaceutical Contract Development and Manufacturing Organization (CMO) Global Market Report 2021: COVID-19 Growth and Change to 2030” report has been added to ResearchAndMarkets.com’s offering.
The global pharmaceutical contract development and manufacturing organization (CMO) market is expected to grow from $97.38 billion in 2020 to $103.24 billion in 2021 at a compound annual growth rate (CAGR) of 6%. The market is expected to reach $149.44 billion in 2025 at a CAGR of 9.7%.
Major players in the pharmaceutical contract development and manufacturing organization (CMO) market are Recipharm AB, Pfizer Inc., Boehringer Ingelheim International GmbH., Aenova Group, Famar, Jubilant Life Sciences Limited, Catalent Pharma Solutions, Chemicals Limited, Dishman Pharmaceuticals and HAUPT Pharma AG.
The pharmaceutical contract development and manufacturing market consists of sales of pharmaceutical contract development and manufacturing products and related services. Some pharmaceutical companies outsource the manufacturing of products on contracts to focus on the R&D, marketing and branding of their products. The pharmaceutical contract development and manufacturing market consists of manufacturing firms who manufacture drugs and other pharmaceutical products for other pharmaceutical companies on contractual basis.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
The pharmaceutical contract development and manufacturing organization (CMO) market covered in this report is segmented by type into active pharmaceutical ingredient (API) manufacturing, finished dosage formulation (FDF) development and manufacturing, secondary packaging. It is also segmented by research phase into preclinical, phase I, phase II, phase III, phase IV.
The pharmaceutical contract development and manufacturing market is restricted by the poor-capacity utilization of manufacturing facilities. The capacity utilization is calculated considering the full potential capacity of the production plant. The poor-capacity utilization of the production plant is caused due to the inefficiency of different sub-processes in the production line which results in low production.
Source: Yahoo Finance
